Several lines of laboratory research, bioinformatics studies as well as meta-analyses have shown that OPN levels can also be considered as a biomarker for diagnosis or as a predicting tool for patient clinical outcome in several types of cancer, such as lung adenocarcinoma, esophageal carcinoma, prostate cancer, melanoma, and colorectal adenocarcinoma. The gene discussed is SPP1; the disease is cancer.